The up-sized offering is on top of a $50 million at-the-market offering that was also completed. The Challenges For Reasonable Strategies For Laser Eye Surgery | Eva Clark CityObviously, the rapid run-up in shares did little to curb investor appetite for this company’s stock. After the completion of these capital raises, Aerie Pharmaceuticals will add $125 million, minus fees, to its coffers and that should give it plenty of financial firepower to finish up preparations for a Rhopressa launch and to get Roclatan’s application buttoned up by late next year. Overall, the size of the glaucoma market makes this company intriguing, especially now that its pipeline is a little more secure. Therefore, risk-tolerant investors may want to add this stock to their watch lists and look for an entry point. A secret billion-dollar stock opportunity The world’s biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn’t miss a beat: There’s a small company that’s powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! Recognising Straightforward Tactics Of Eye Surgery | Guidance To The ViewTo be one of them, just click here . Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B.
For the original version including any supplementary images or video, visit http://www.foxbusiness.com/markets/2016/09/16/why-aerie-pharmaceuticals-shares-are-rallying-another-11-today.html